{"id":479642,"date":"2021-04-21T09:03:28","date_gmt":"2021-04-21T13:03:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/"},"modified":"2021-04-21T09:03:28","modified_gmt":"2021-04-21T13:03:28","slug":"robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/","title":{"rendered":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the <i>CytoDyn, Inc.<\/i> Class Action Lawsuit<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rgrdlaw.com&amp;esheet=52415448&amp;newsitemid=20210421005271&amp;lan=en-US&amp;anchor=Robbins+Geller+Rudman+%26amp%3B+Dowd+LLP&amp;index=1&amp;md5=b398d5685730768cb45c0a7d95ff7339\">Robbins Geller Rudman &amp; Dowd LLP<\/a> announces that purchasers of CytoDyn, Inc. (OTC:CYDY) common stock between March 27, 2020 and March 9, 2021, inclusive (the \u201cClass Period\u201d) have until May 17, 2021 to seek appointment as lead plaintiff in the <i>CytoDyn<\/i> class action lawsuit, <i>Lewis v. CytoDyn, Inc<\/i>., No. 21-cv-05190 (W.D. Wash.), which is assigned to Judge Benjamin H. Settle.\n<\/p>\n<p>\nThe Private Securities Litigation Reform Act of 1995 permits any investor who purchased CytoDyn common stock during the Class Period to seek appointment as lead plaintiff in the <i>CytoDyn <\/i>class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the <i>CytoDyn <\/i>class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the <i>CytoDyn<\/i> class action lawsuit. An investor\u2019s ability to share in any potential future recovery of the <i>CytoDyn<\/i> class action lawsuit is not dependent upon serving as lead plaintiff. <b>If you wish to serve as lead plaintiff of the <i>CytoDyn <\/i>class action lawsuit or have questions concerning your rights regarding the <i>CytoDyn<\/i><\/b><i \/><b>class action lawsuit, please provide your information <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-cytodyn-inc-class-action-lawsuit.html&amp;esheet=52415448&amp;newsitemid=20210421005271&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=a129f78a0faf2e515808a0c03fe1e3db\">here<\/a> or contact counsel, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rgrdlaw.com%2Fattorneys-Juan-Carlos-Sanchez.html&amp;esheet=52415448&amp;newsitemid=20210421005271&amp;lan=en-US&amp;anchor=J.C.+Sanchez&amp;index=3&amp;md5=55f285458778ceff76652126d7afc742\">J.C. Sanchez<\/a> of Robbins Geller, at 800\/449-4900 or 619\/231-1058 or via e-mail at <a rel=\"nofollow\" href=\"mailto:jsanchez@rgrdlaw.com\">jsanchez@rgrdlaw.com<\/a>. Lead plaintiff motions for the<i> CytoDyn<\/i><\/b><i \/><b>class action lawsuit must be filed with the court no later than May 17, 2021.<\/b><\/p>\n<p>\nCytoDyn is a biotechnology company focused on the development and commercialization of a drug named \u201cLeronlimab\u201d which has long been promoted as a potential therapy for HIV patients.\n<\/p>\n<p>\nThe <i>CytoDyn<\/i> class action lawsuit alleges that since the beginning of the global COVID-19 pandemic, CytoDyn has begun to aggressively tout Leronlimab as a treatment for COVID-19. Consequently, after CytoDyn\u2019s pivot to hyping Leronlimab as a treatment for COVID-19, CytoDyn\u2019s stock price rose exponentially. The <i>CytoDyn<\/i> class action lawsuit further alleges that while CytoDyn\u2019s stock price was sufficiently pumped with the COVID-19 cure hype, defendants dumped millions of shares at artificially inflated prices. Moreover, the <i>CytoDyn<\/i> class action lawsuit alleges that CytoDyn also engaged in a wrongful scheme with its lender, Iliad Research and Trading L.P. and its principal John Fife whereby Iliad and other Fife entities operated as an unregistered securities dealer for CytoDyn. In connection with Iliad lending funds to CytoDyn, Iliad obtained a convertible promissory note from CytoDyn and converted the note into newly issued shares of CytoDyn and sold those shares into the public market at a profit, in alleged violation of the dealer registration requirements of the federal securities laws.\n<\/p>\n<p>\nOn August 26, 2020, <i>The Wall Street Journal <\/i>reported that, despite earlier representations, CytoDyn was not being considered for Operation Warp Speed. According to a senior administration official interviewed by <i>The Wall Street Journal<\/i>, \u201cCytoDyn had only completed a preliminary qualification for being included in the initiative.\u201d On this news, the price of CytoDyn shares dropped more than 17% over the next two trading days.\n<\/p>\n<p>\nThen, on September 3, 2020, the U.S. Securities and Exchange Commission (\u201cSEC\u201d) filed a lawsuit against Iliad, Fife, and certain Fife-related entities, calling Fife a \u201crecidivist violator of the federal securities laws.\u201d Specifically, the SEC alleged that Iliad and its related entities operated as unregistered securities dealers in violation of the federal securities laws by buying convertible promissory notes, converting the notes into newly issued shares of stock, then rapidly selling those shares into the public at a profit.\n<\/p>\n<p>\nThereafter, on November 10, 2020, CytoDyn entered into an amended $28.5 million Secured Convertible Promissory Note with Fife\u2019s company, Streeterville Capital LLC, a related entity that was not specifically named in the SEC action against Iliad and Fife. On this news, the price of CytoDyn\u2019s shares fell.\n<\/p>\n<p>\nFinally, on March 5, 2021, and continuing over the weekend, CytoDyn issued a flurry of press releases describing the results of Phase IIb\/III data on Leronlimab. Hidden in press releases with titles like \u201cCytodyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19\u201d and \u201cCytodyn\u2019s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab,\u201d however, was a disclosure that the primary endpoint of the study \u2013 lowering all-cause mortality at Day 28 \u2013 was not statistically significant. Following the flurry of press releases, CytoDyn was accused of \u201cmassaging the data\u201d and squeezing good news out of a failed study, the results of which CytoDyn reportedly sat on pending regulatory discussions. On this news, the price of CytoDyn\u2019s shares fell more than 28%, further damaging investors.\n<\/p>\n<p>\nRobbins Geller Rudman &amp; Dowd LLP is one of the world\u2019s leading law firms representing investors in securities class action litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. ISS Securities Class Action Services has ranked Robbins Geller as one of the top law firms in the world in both amount recovered and total number of class action settlements for shareholders every year since 2010. The SCAS 2020 Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other plaintiffs\u2019 firm. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations, and the media as leading lawyers in the industry. Please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rgrdlaw.com&amp;esheet=52415448&amp;newsitemid=20210421005271&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.rgrdlaw.com&amp;index=4&amp;md5=9a1779b375b6cfd64c925ff8ebdc69fd\">http:\/\/www.rgrdlaw.com<\/a> for more information.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210421005271\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210421005271\/en\/<\/a><\/span><\/p>\n<p>\nRobbins Geller Rudman &amp; Dowd LLP<br \/>\n<br \/>J.C. Sanchez, 800-449-4900<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jsanchez@rgrdlaw.com\">jsanchez@rgrdlaw.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210421005271\/en\/221960\/3\/RGRD_FINAL.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of CytoDyn, Inc. (OTC:CYDY) common stock between March 27, 2020 and March 9, 2021, inclusive (the \u201cClass Period\u201d) have until May 17, 2021 to seek appointment as lead plaintiff in the CytoDyn class action lawsuit, Lewis v. CytoDyn, Inc., No. 21-cv-05190 (W.D. Wash.), which is assigned to Judge Benjamin H. Settle. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased CytoDyn common stock during the Class Period to seek appointment as lead plaintiff in the CytoDyn class action lawsuit. A lead plaintiff is generally the movant with the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479642","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of CytoDyn, Inc. (OTC:CYDY) common stock between March 27, 2020 and March 9, 2021, inclusive (the \u201cClass Period\u201d) have until May 17, 2021 to seek appointment as lead plaintiff in the CytoDyn class action lawsuit, Lewis v. CytoDyn, Inc., No. 21-cv-05190 (W.D. Wash.), which is assigned to Judge Benjamin H. Settle. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased CytoDyn common stock during the Class Period to seek appointment as lead plaintiff in the CytoDyn class action lawsuit. A lead plaintiff is generally the movant with the &hellip; Continue reading &quot;Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T13:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit\",\"datePublished\":\"2021-04-21T13:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/\"},\"wordCount\":1027,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/\",\"name\":\"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-21T13:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit - Market Newsdesk","og_description":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of CytoDyn, Inc. (OTC:CYDY) common stock between March 27, 2020 and March 9, 2021, inclusive (the \u201cClass Period\u201d) have until May 17, 2021 to seek appointment as lead plaintiff in the CytoDyn class action lawsuit, Lewis v. CytoDyn, Inc., No. 21-cv-05190 (W.D. Wash.), which is assigned to Judge Benjamin H. Settle. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased CytoDyn common stock during the Class Period to seek appointment as lead plaintiff in the CytoDyn class action lawsuit. A lead plaintiff is generally the movant with the &hellip; Continue reading \"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T13:03:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit","datePublished":"2021-04-21T13:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/"},"wordCount":1027,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/","name":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-21T13:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210421005271r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-announces-lead-plaintiff-deadline-in-the-cytodyn-inc-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Robbins Geller Rudman &amp; Dowd LLP Announces Lead Plaintiff Deadline in the CytoDyn, Inc. Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479642"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479642\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}